Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer
He Y, Song L, Wang H, Chen P, Liu Y, Sun H, Li X, Dang S, Liu G, Liu X, Chen S, Zhang X, Hofman P, Uchino J, Park HS, Pacheco JM, Tabbò F, Xu M, Dai J, He K, Yang Y, Zhou C, Group W. Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer. Advanced Science 2020, 8: 2003263. PMID: 33643802, PMCID: PMC7887584, DOI: 10.1002/advs.202003263.Peer-Reviewed Original ResearchFirst-line chemotherapyLung cancer patientsLong-term survivalNSCLC patientsCancer patientsLung cancerTherapeutic responseProgression-free survivalMolecular signaturesWhole-exome sequencingLine chemotherapySCLC patientsFree survivalWorse survivalHigh TMBTherapeutic decisionsResults HistologyMolecular subtypesPatientsChemotherapyDifferent subtypesSubtypesLimited biomarkersTissue samplesSurvivalUse of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy.
Yang D, Jairam V, Park H, Decker R, Chiang A, Gross C, Yu J. Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy. Journal Of Clinical Oncology 2020, 38: e19309-e19309. DOI: 10.1200/jco.2020.38.15_suppl.e19309.Peer-Reviewed Original ResearchExtensive-stage small-cell lung cancerFirst-line chemoSmall cell lung cancerES-SCLC patientsCell lung cancerSurvival benefitIO patientsLung cancerStudy periodFirst-line atezolizumabInitial systemic therapyProphylactic cranial irradiationFirst-line chemotherapyRetrospective cohort analysisContemporary practice patternsDe-identified databaseUse of PCIEffectiveness of PCICHEMO patientsCranial irradiationIO therapyPCI useSystemic therapyMRI surveillancePractice patterns